论文部分内容阅读
目的探讨阿替普酶静脉溶栓治疗急性缺血性脑卒中患者的临床疗效及安全性。方法选取荥阳市人民医院2015年4月—2016年6月收治的急性缺血性脑卒中患者102例,根据不同的治疗分为对照组和观察组,各51例。对照组患者给予常规治疗,观察组患者在对照组基础上给予阿替普酶静脉溶栓治疗,两组患者均持续治疗7d。比较两组患者的临床疗效,治疗前及治疗后24 h、7 d美国国立卫生院卒中量表(NIHSS)评分、格拉斯昏迷量表(GCS)评分,统计并比较两组患者治疗期间不良反应发生情况。结果观察组患者临床疗效优于对照组(P<0.05)。治疗前,两组患者NIHSS评分、GCS评分比较,差异无统计学意义(P>0.05);治疗后24 h、7 d,观察组患者NIHSS评分均低于对照组,GCS评分高于对照组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论阿替普酶静脉溶栓急性缺血性脑卒中患者的临床疗效确切,可有效改善患者神经功能缺损程度及意识状态,且安全性高。
Objective To investigate the clinical efficacy and safety of intravenous infusion of alteplase in patients with acute ischemic stroke. Methods 102 cases of acute ischemic stroke admitted to Shenyang People’s Hospital from April 2015 to June 2016 were divided into control group and observation group according to different treatment, with 51 cases in each group. Patients in the control group were given routine treatment. Patients in the observation group were given intravenous thrombolysis with alteplase on the basis of the control group, and both groups were treated for 7 days. The clinical curative effect, NIHSS score and GCS score at 24 h and 7 d after treatment were compared between the two groups. Statistics and comparison of adverse reactions What happened? Results The clinical efficacy of the observation group was better than that of the control group (P <0.05). Before treatment, there was no significant difference between the two groups in the NIHSS score and the GCS score (P> 0.05). At 24 and 7 days after treatment, the NIHSS scores of the observation group were lower than those of the control group, and the GCS score was higher than that of the control group P <0.05). Two groups of patients with adverse reactions, the difference was not statistically significant (P> 0.05). Conclusion Alteplase intravenous thrombolysis in patients with acute ischemic stroke clinical curative effect is exact, can effectively improve the degree of patients with neurological deficit and consciousness, and high safety.